AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets January 11, 2023
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for 7 Investigational ADC Candidates for the Treatment of Cancer January 4, 2023
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics January 4, 2023
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck to Develop Novel Immunosynthen ADCs January 4, 2023
Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer January 4, 2023
mOS of 21 Months in Advanced, Refractory Cancer Patients observed in Ph 2 trial of PDS0101-based triple combination therapy in advanced HPV-positive cancers January 4, 2023
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy December 13, 2022
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors December 13, 2022
Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Ph 1 Trial of NTX1088 for Advanced Solid Tumors December 5, 2022
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers November 30, 2022
Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases November 23, 2022
Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline November 16, 2022
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors November 16, 2022
MGFB announces agreement with Mayo Clinic for development of novel therapeutic cancer vaccines November 16, 2022
Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence November 16, 2022
First Patient Dosed in Ph 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors November 16, 2022
Voluntary Pause of Enrollment in Ongoing in ITIL-168 and ITIL-306 Trials Related to Manufacturing November 16, 2022
Dose Escalation Data from transcendIT-101 Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors Presented November 16, 2022
Interim Analysis of Ph 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2) provided November 16, 2022
Promising Initial Dose-Escalation Results from Ph 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors announced November 16, 2022
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with BMS November 4, 2022
